Saniona AB
6 Apr - 20 Apr 2021Warrant exercise TO 3
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world.
The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION)
Read more at the Company's website
The offer in summary
Terms: One (1) warrant of series TO 3 will give the holder the right to subscribe for one (1) new share in Saniona AB
Subscription period: April 2021
Number of warrants series TO 3: 1 479 742
Subscription price: 70% of the volume weighted average price during 17 March 2021 - 30 March 2021
